|
|
News Breaks | | | | November 4, 2012 | | 11:34 EDT |  | ALXN | Alexion:Data show long-term benefits of chronic Soliris therapy in aHUS patients
Alexion Pharmaceuticals announced the presentation of two-year data that highlight the long-term benefits of chronic Soliris, eculizumab, therapy in patients with atypical hemolytic uremic syndrome, aHUS, an ultra-rare genetic disease characterized by thrombotic microangiopathy, TMA, the formation of blood clots in small blood vessels throughout the body. In two pivotal phase 2 studies, which initially enrolled 37 patients, 32 patients entered a long-term extension phase. The data demonstrated that ongoing Soliris treatment for two years was associated with sustained inhibition of complement-mediated TMA, as indicated by a maintained increase in platelet count, and sustained improvement in renal function and TMA event-free status.1,2 The data were presented today at Kidney Week 2012, the annual meeting of the American Society of Nephrology, ASN, in San Diego. Additionally, data presented in a poster session at ASN support early initiation of Soliris therapy regardless of the presence or absence of genetic mutations in patients with aHUS. | |
|
News For ALXN From The Last 14 Days Check below for free stories on ALXN the last two weeks. |
|
|
| There are no results for ALXN |
|
|
|
|
|
|
